Operates a hospital-based healthcare business alongside a large pharmacy distribution network and a retail diagnostics chain. In FY26, total revenue was Rs 25,228.5 crore with net profit of Rs 2,002.7 crore. The Healthcare services segment contributed 50.1% of segment revenue (Rs 12,750.1 crore) at a 19.1% EBIT margin, while Digital health & pharmacy distribution contributed 42.5% (Rs 10,808.1 crore) at a 3.7% EBIT margin, and Retail health & diagnostics contributed 7.3% (Rs 1,865.3 crore) at a 3.9% EBIT margin. Major cost lines are other operating expenses at 21.3% of revenue, materials at 12.1% and employee costs at 11.9%, with depreciation at 3.5% and capex of Rs 1,962.0 crore (7.8% of revenue) in the year. The company has filed a composite scheme of arrangement to demerge an identified business undertaking (including Apollo Healthco and Keimed) into a new listed entity called Apollo Healthtech, with equity shareholders having approved the scheme at NCLT-convened meetings in June 2026. AR · MarketPing reader · 2026-08-03
Revenue streams, as the annual report describes them. Healthcare services (50%), Digital health & pharmacy distribution (43%), Retail health & diagnostics (7%), Others (0%). Asset-heavy hospital operator with a lower-margin, large-volume pharmacy distribution arm and a small retail diagnostics business.
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 14,663 | 16,612 | 19,059 | 21,794 | 25,229 |
| EBITDA (ex other income) | 2,479 | 2,050 | 2,393 | 3,022 | 3,750 |
| margin % | 16.9 | 12.3 | 12.6 | 13.9 | 14.9 |
| Owners' profit | 1,056 | 819 | 899 | 1,446 | 1,942 |
| EPS, as reported (₹) | 73.42 | 56.97 | 62.50 | 100.56 | 135.04 |
| ROE % · ROCE % | 18.8 · 18.1 | 12.9 · 13.7 | 12.8 · 15.0 | 17.4 · 15.3 | 20.1 · 19.5 |
| Debt / equity (x) | 0.45 | 0.41 | 0.43 | 0.61 | 0.57 |
| Cash from operations | 1,616 | 1,377 | 1,920 | 2,136 | 2,856 |
| Capex | (657) | (1,129) | (1,137) | (1,713) | (1,962) |
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 5,589 | 5,527 | 5,592 | 5,842 | 6,304 | 6,477 | 6,606 | 7,044 |
| Profit before tax | 552 | 531 | 505 | 569 | 668 | 667 | 711 | 785 |
| Net profit | 396 | 379 | 415 | 441 | 494 | 516 | 551 | 610 |
| EPS (₹) | 26.34 | 25.89 | 27.10 | 30.10 | 33.19 | 34.94 | 36.82 | 40.39 |
| Segment | Revenue, ₹ crore | Share % |
|---|---|---|
| Healthcare services | 3,334 | 13.1 |
| Retail health & diagnostics | 490 | 1.9 |
| Digital health & pharmacy distribution | 2,848 | 11.2 |
| Others | 1 | 0.0 |
| a) Healthcare services | 9,416 | 37.0 |
| b) Retail health and diagnostics | 941 | 3.7 |
| c) Digital health and pharmacy distribution | 5,488 | 21.6 |
| d) Others | 4 | 0.0 |
| b) Retail Health & diagnostics | 435 | 1.7 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 3 Sept 2026 · Newspaper ads published for IEPF share transfer notice | compliance | minimal | — | — |
| 28 Aug 2026 · Updated Annual Report for FY 2025-26 resubmitted to fix editorial omission | investor communications | low | — | — |
| 25 Aug 2026 · Apollo Hospitals 45th AGM: all 8 resolutions passed with strong majority | board shareholder meetings | low | — | — |
| 25 Aug 2026 · Apollo Hospitals 45th AGM: All 8 resolutions passed, Rs 7,500 mn NCD issue approved | board shareholder meetings | medium | — | — |
| 25 Aug 2026 · Apollo Hospitals 45th AGM proceedings and voting results | board shareholder meetings | medium | — | — |
| 19 Aug 2026 · Transcript of Q1 FY27 earnings call posted on company website | investor communications | medium | — | — |
| 13 Aug 2026 · Audio recording of Q1 FY27 analyst call available on website | investor communications | low | — | — |
| 13 Aug 2026 · Analyst call audio for Q1 FY27 results uploaded | investor communications | low | — | — |
| 12 Aug 2026 · Apollo Hospitals Q1 FY27: Revenue up 21%, PAT up 34%, 1000 new beds added | investor communications | medium | — | — |
| 12 Aug 2026 · Apollo Hospitals Q1 FY27 Investor Presentation: Revenue up 21%, PAT up 34% | investor communications | medium | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| c) Digital health & pharmacy distribution |
| 2,472 |
| 9.7 |
| Total, before eliminations | 25,429 | 100.0 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| APOLLO HOSPITALS ENTER. L ◆ | 1,27,062 | 60.8 | 12.74 | 33.5 | 20.1 | 16.6 | 19.0 | 16.2 |
| MAX HEALTHCARE INS LTD | 1,00,993 | 69.2 | 9.40 | 44.0 | 13.4 | 11.1 | 27.3 | 27.0 |
| FORTIS HEALTHCARE LTD | 67,025 | 64.0 | 6.59 | 32.9 | 10.5 | 9.7 | 17.8 | 22.0 |
| ASTER DM QUALITY CARE LTD | 39,689 | 124.0 | 8.21 | 40.4 | 8.8 | 8.5 | (11.6) | 14.3 |
| GLOBAL HEALTH LIMITED | 38,972 | 70.0 | 9.78 | 39.4 | 13.9 | 13.5 | — | 23.7 |
| NARAYANA HRUDAYALAYA LTD. | 38,213 | 46.5 | 8.42 | 25.4 | 17.8 | 9.2 | 25.0 | 18.8 |
| KRISHNA INST OF MED SCI L | 32,235 | 150.5 | 12.60 | 43.4 | 9.5 | 5.1 | 24.0 | 20.3 |
| DR AGARWALS HEALTH CARE L | 16,043 | 107.9 | 7.57 | 26.2 | 7.9 | 7.1 | — | 28.8 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 60.8 | 47.3 | 22 of 30 | 28% |
| P/B | 12.7 | 6.2 | 24 of 24 | 0% |
| ROCE | 16.6 | 10.9 | 3 of 30 | 93% |
| ROE | 20.1 | 11.8 | 4 of 24 | 87% |
| Debt / Equity | 0.6 | 0.2 | 21 of 24 | 13% |
| EBITDA margin | 16.2 | 22.0 | 21 of 24 | 13% |
| Revenue growth | 20.6 | 20.2 | 11 of 23 | 55% |
| Profit growth | 38.4 | 8.1 | 6 of 21 | 75% |
| Market cap | 127062 | 2415 | 1 of 30 | 100% |
| A rating (BUY / ADD / REDUCE / SELL) |
| A state: the latest filed quarter and the measured reactions |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
